AnaptysBio
ANAB
113 hedge funds and large institutions have $675M invested in AnaptysBio in 2023 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 35 increasing their positions, 36 reducing their positions, and 20 closing their positions.
10% more call options, than puts
Call options by funds: $1.47M | Put options by funds: $1.34M
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3% less repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 36
1.53% less ownership
Funds ownership: 112.66% → 111.13% (-1.5%)
4% less funds holding
Funds holding: 118 → 113 (-5)
25% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 20
32% less capital invested
Capital invested by funds: $993M → $675M (-$317M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$19.2M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
+$6M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$3.88M |
| 4 |
Goldman Sachs
New York
|
+$1.9M |
| 5 |
Renaissance Technologies
New York
|
+$1.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$25.1M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$14.5M |
| 3 |
DM
Deerfield Management
New York
|
-$13.3M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$10.8M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
-$7.75M |
ANAB Hedge Fund Activity: Q1 2023 in Review
113 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in AnaptysBio (ANAB) for Q1 2023, worth a combined $675M — down 32% from $993M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of ANAB and 15 opened new positions — a net loss of 5 holders — while 36 trimmed existing stakes and 35 added.
The largest buyer was Great Point Partners, adding an estimated $19.2M. The largest seller was Federated Hermes, cutting an estimated $25.1M.
- 113 institutional investors held AnaptysBio (ANAB) as of Q1 2023, down from 118 in Q4 2022.
- Funds reported $675M of AnaptysBio stock for Q1 2023, down 32% quarter-over-quarter.
- 15 funds opened new AnaptysBio positions in Q1 2023 and 20 closed out, a net change of -5 holders.
- The largest AnaptysBio buyer in Q1 2023 was Great Point Partners, an estimated $19.2M added.
- The largest AnaptysBio seller in Q1 2023 was Federated Hermes, an estimated $25.1M sold.
Based on aggregated 13F filings for Q1 2023.